Clinical Trial Update: Efficacy and Safety of BG00012 in MS [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating efficacy and safety of BG00012 in multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• BG00012 (dimethyl fumarate)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED